Knowles (KN) Investor Day 2025 summary

Strategic transformation and business focus

• Completed a five-year transformation, divesting consumer MEMS microphones and focusing on MedTech, Defense, Industrial, and Energy markets, with a portfolio now split between Precision Devices (54% of revenue) and MedTech & Specialty Audio (46%).

• Over 95% of revenue now comes from MedTech, Defense, and Industrial markets, with a high-margin product portfolio.

• Portfolio repositioned through four acquisitions and two divestitures, including exit from consumer MEMS microphones.

• Emphasizes customization at scale, deep engineering expertise, and advanced manufacturing capabilities as key differentiators.

• Strong balance sheet and robust cash generation support future growth and shareholder returns.

Financial performance and guidance

• Achieved 8% revenue CAGR and 11% adjusted EBITDA CAGR from 2017–2024, with EBITDA margins improving by 400 bps.

• For 2025, expects $560–$590 million in revenue, $140–$150 million adjusted EBITDA, and $80–$100 million cash from operations.

• Over the next five years, targets 8–10% total revenue CAGR (4–6% organic, 4% from M&A), 10–14% adjusted EBITDA CAGR, and 16–20% operating cash flow as a percentage of revenue.

• Capital allocation priorities: 3–5% of revenue to CapEx, increased M&A focus, and opportunistic share repurchases.

• Margin expansion driven by price optimization, lean manufacturing, cost controls, and disciplined expense management.

Growth initiatives and new product development

• Precision Devices segment expects 6–8% organic CAGR, driven by market growth, new integrated capacitor solutions, expansion into inductors, and specialty film capacity ramp-up.

• MedTech & Specialty Audio segment targets 2–4% organic CAGR, leveraging leadership in hearing health and new medtech micro solutions.

• Specialty film capacitors and ceramic inductors are new product lines, with specialty film expected to reach $50–$60 million revenue in 2026 and inductors contributing in 3–5 years.

• Micro solutions for medtech (e.g., diagnostics, cardiac rhythm management) expected to start production in 2026, leveraging core manufacturing competencies.

• Large $75+ million energy order secured, with production ramping in 2026 at above-average margins.